52 results about "Myostatin" patented technology

The present disclosure relates to antibodies and antigen-binding fragments that specifically bind to a promyostatin / latent myostatin and uses thereof.

The invention discloses application of serum MSTN (myostatin) as a marker in preparation of a metabolism-related steatohepatitis diagnosis product, and belongs to the technical field of biomedical detection. The biomarker for noninvasive diagnosis of the metabolism-related steatohepatitis is serum myosostatin MSTN, and the biomarker can be used as a detection target for preparing a noninvasive diagnosis product of the metabolism-related steatohepatitis. As an independent biomarker, the MSTN is higher in diagnosis efficiency in AST normal patients; the MSTN and the ALT or the AST are jointly applied, so that the specificity and the positive predictive value (PPV) of single use of the ALT or the AST can be improved, the misdiagnosis rate of the ALT or the AST can be reduced, non-MASH patients can be more accurately excluded, and unnecessary, invasive or expensive subsequent examinations are reduced.

The present invention addresses the problem of providing a method for improving the fleshiness of fish. The problem is solved by a method for improving the fleshiness of fish, the method including suppressing the expression of the function of myostatin in fish.

Provided herein are methods for improving glycemic control in a human patient, methods for treating, preventing or reducing overweight or obesity and related co-conditions, and methods for treating or preventing type II diabetes mellitus by administering a polypeptide to the patient, the polypeptide comprises a fibronectin type III tenth (10Fn3) domain that binds to a myostatin. In some embodiments, the polypeptides are administered according to a specific clinical dosing regimen (e.g., at a specific dose and according to a specific time interval) (or for administration according to the regimen).

Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and / or latent Myostatin and uses thereof.

A novel preventive and / or therapeutic agent useful in the prevention and / or treatment of a disease whose symptom is alleviated or improved by the inhibition of myostatin. The present invention relates to an agent for preventing and / or treating a disease whose symptom is alleviated or improved by the inhibition of myostatin, the agent including a therapeutically effective dose of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof.

Disclosed herein are therapeutic uses of myostatin-selective inhibitors, such as myostatin-selective inhibitors, for treating metabolic disorders, such as obesity. Data presented herein support the notion that selectively targeting myostatin without inhibiting Activin A can achieve equivalent or enhanced efficacy when used in conjunction with a GLP-1 receptor agonist in improving body composition, as compared to broadly antagonizing the ActRII pathway in conjunction with a GLP-1 receptor agonist. Administration of a myostatin-selective inhibitor can prolong the effect of semaglutide on fat mass loss. Moreover, administration of a myostatin-selective inhibitor can elicit positive effects on bone in all parameters evaluated, indicating that diet- or inflammation-induced bone atrophy may be prevented by selective inhibition of the myostatin pathway.

The present invention relates a pharmaceutical composition for alleviation, treatment, and prevention of sarcopenia, including, as an active ingredient, a microorganism transformed with a cell surface display vector operably linked with a gene encoding myostatin and activin A proteins.

The present invention relates to: a cultured meat medium additive and a cultured meat medium composition that can induce muscle growth by differentiating muscle stem cells into muscle cells and inhibiting the expression of myostatin, which inhibits muscle growth; and a method for preparing cultured meat by using same. Specifically, the cultured meat medium additive and the cultured meat medium composition comprise laxogenin and 5-alpha hydroxy laxogenin.

The present disclosure relates to antibodies and antigen-binding fragments that specifically bind to pro / latent myostatin and uses thereof.

The invention features methods of treating a subject having Duchenne muscular dystrophy by administering an activin A and myostatin signaling inhibitor in combination with a dystrophin exon skipping therapy. The activin A and myostatin signaling inhibitor may be an activin A antibody or an antigen binding fragment thereof and an anti-myostatin protein (e.g., a myostatin antibody or an antigen binding fragment thereof or an anti-myostatin adnectin recombinant protein), an ActRII antibody or an antigen binding fragment thereof, or an extracellular ActRII ligand trap.

Provided are a double-stranded siRNA analog for inhibiting myostatin (MSTN) expression, a preparation method therefor, and use thereof. The double-stranded siRNA analog can inhibit MSTN expression and be used for preventing and / or treating MSTN-related diseases and disorders, such as myoatrophy.

The present disclosure relates to antibodies and antigen-binding fragments that specifically bind to pro / latent myostatin and uses thereof.

The present invention provides a method for determining whether a patient will respond to treatment with a myostatin pathway inhibitor, the method comprising: (a) determining a level of myostatin and / or activin type II receptor (ActRII) and / or follistatin in at least one muscle biopsy obtained from a treatment target muscle in a subject having or suspected of having muscle atrophy or a muscle wasting condition; and (b) determining a level of myostatin and / or follistatin in a systemic sample obtained from the patient, wherein if: (i) the level of myostatin in the systemic sample is higher than a threshold and / or if the level of follistatin in the sample is lower than a threshold; and (ii) the level of myostatin and / or ActRII receptor in the at least one biopsy sample is higher than a threshold level and / or if the level of follistatin in the at least one biopsy sample is lower than a threshold level, the patient will respond to treatment.

This invention discloses an instant gelling powder of sodium alginate / calcium β-hydroxy-β-methylbutyrate with dual functions of fat reduction and muscle gain, and its application, belonging to the field of functional food or pharmaceutical preparation technology. The powder of this invention is prepared by dry mixing sodium alginate and CaHMB at a weight ratio of 5~10:1~5, preferably 7:3, wherein the guluronic acid content of sodium alginate is ≥50%. In use, 1g of powder is added to 20~40mL of water at 60~100°C, and stirred to form a hydrogel. After oral administration, the powder rapidly forms a gel in the stomach, producing a feeling of fullness, and simultaneously achieves fat reduction, muscle gain, and metabolic regulation functions by regulating myostatin expression. This invention overcomes the limitation of existing weight management products with only one function, innovatively integrating the three major effects of instant satiety, fat reduction, and muscle gain. The preparation process is simple and environmentally friendly, requiring no added chemical excipients, and has significant technological advancement and market application value.

A method for constructing a mouse model for rapid degradation of Myostatin (MSTN) protein is provided. The method includes: inserting sequentially a 5′ homologous arm, 3 X (Glu-Ala-Ala-Ala-Lys) (3xEAAAK), an FK506-binding protein (FKBP1A) gene synonymous mutation sequence, 3xEAAAK, a red fluorescent protein monomeric Cherry (mCherry) sequence and a 3′ homologous arm into a Donor vector backbone to obtain a Donor recombinant vector; designing a Guide Ribonucleic Acid (gRNA) based on a third exon of the Mstn gene; mixing the gRNA, CRISPR-associated protein 9 (Cas9) protein, and the Donor recombinant vector and co-injecting a mixture of the above into mouse fertilized eggs, culturing the fertilized eggs in vitro and transplanting to obtain the F0 generation mice; and hybridizing the F0 generation mice with wild-type mice, or further breeding hybridized offspring to obtain a knock-in mouse model.

The present invention relates to a combination therapy of an approved GLP-1 receptor agonist treatment and a microorganism transformed with a cell surface display vector operably linked with a gene encoding myostatin and activin A proteins for the treatment of muscle loss related to obesity. The microorganism may be formulated to include pharmaceutically viable excipients, such as antiadherents, binders, carriers, coatings, colorants, disintegrants, diluents, flavorings, glidants, lubricants, preservatives, sorbents, or vehicles.

The invention features methods of treating a subject having myelofibrosis by co-administering an activin receptor type II (ActRII) signaling inhibitor and a myelofibrosis therapy. The ActRII signaling inhibitor may be an antibody that binds to an ActRII ligand, an ActRII antibody, an ActRII ligand trap, or an anti-myostatin adnectin recombinant protein.

The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.

The present invention relates to a pharmaceutical composition for preventing or treating muscle diseases. Specifically, the elderberry extract or monosaccharide and amino acid combined compound disclosed by the invention inhibits apoptosis of muscle cells, inhibits expression of inflammatory cytokines, promotes secretion of testosterone and inhibits expression of amyotrophy marker protein and myogenesis inhibition protein, and shows an effect of recovering muscle in a sarcopenia animal model; therefore, the device can be effectively used in the treatment of muscle diseases.

The invention relates to an MSTN (myostatin) gene molecular marker related to a pigeon body weight character and application of the MSTN gene molecular marker, and belongs to the technical field of biology. According to the invention, genome DNA of a to-be-detected pigeon is taken as a template, PCR amplification is carried out on the to-be-detected pigeon by using an SNP primer, then Sanger sequencing and SNP molecular marker genotyping are carried out on a PCR amplification product, and then pigeon body weight traits are selected. The weight of G / G genotype pigeons is higher than that of A / G and A / A genotype individuals, and the weight of A / G genotype pigeons is higher than that of A / A genotype individuals. By eliminating A / G and A / A genotype individuals and retaining G / G genotype individuals, the molecular marker has the beneficial effects that the molecular marker is used as a genetic marker for breeding pigeons, and the pigeons with large weight and uniformity are bred; the method can efficiently and quickly identify the weight traits of the pigeons, improves the uniformity of the weight of pigeons, provides a scientific basis for the early breeding of the pigeons, and better serves the breeding of the pigeons.

The application discloses a primer set for real-time fluorescent quantitative PCR detection of a pig muscle regulatory factor and application thereof, and belongs to the technical field of biology. The application provides specific primer pairs capable of detecting pig muscle regulatory factors MyoD and MyoG and reference primer pairs. cDNA is obtained by extracting sample RNA and performing reverse transcription, and real-time fluorescent PCR is performed by using the provided primers, so that the mRNA expression amount of the pig muscle regulatory factors MyoD and MyoG can be simultaneously detected quickly, specifically, sensitively and stably, and the application can be used for detecting the change in the expression level of the regulatory factors before and after the differentiation of pig muscle stem cells, so that the differentiation condition of pig breeding meat can be judged.

Provided herein are polypeptides that bind myostatin with improved PK properties. Also provided are compositions comprising the same, and methods of using the polypeptides in therapeutic applications to treat neurodegenerative diseases and metabolic disorders.

The present invention relates generally to stable liquid formulations comprising polypeptides with 10Fn3 domains which bind to myostatin and unit dosage forms thereof for administration via various routes, including subcutaneous (SC), for treating muscle-wasting and metabolic disorders.

This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human MSTN mRNA, delivery systems, kits, and compositions comprising the same, and methods of using the same for inhibiting or downregulating MSTN gene expression and treating or preventing a disease or disorder associated with aberrant or increased expression or activity of MSTN or a disease or disorder where MSTN plays a role.

The present invention provides pharmaceutical compositions for treating or preventing metabolic diseases selected from the group consisting of type 1 diabetes, type 2 diabetes, obesity, metabolic syndrome / prediabetes, cardiovascular disease, non-alcoholic steatohepatitis (NASH), spinal cord injury (SCI), hypometabolic state, double diabetes, Cushing's disease, and obesity syndrome. [Solution] A composition for use as a pharmaceutical in the treatment or prevention of metabolic disease in a human subject, comprising the steps of: selecting a human subject who has a metabolic disease or is at risk of developing one, and administering to the human subject an effective amount of the composition comprising the antibody or the antigen-binding fragment.

This disclosure relates to antibodies that specifically bind to tropomyostatin and / or latent myostatin, and their uses.

The present invention relates to a novel therapeutic agent capable of treating muscle diseases, metabolic diseases, and bone diseases by simultaneously inhibiting the activin type II receptor and myostatin. Specifically, the invention relates to a bispecific protein comprising an anti-ActRII antibody and an anti-Myostatin antibody, and the use thereof. The simultaneous inhibition of the activin type II receptor and myostatin according to the present invention exhibits excellent effects of muscle growth and bone differentiation as well as weight loss; thus, it resolves the problem of muscle loss, which is a side effect of existing anti-obesity treatments, and can effectively improve various metabolic diseases. Therefore, the bispecific protein of the present invention can be utilized in various fields for the improvement and treatment of muscle diseases, metabolic diseases, and bone diseases.

This disclosure relates to methods and compositions for inhibiting expression and / or activity levels of nuclear receptor corepressor 1 (NC0R1) and / or myostatin (MSTN) to treat various diseases or disorders.